AURINIA PHARMACEUTICALS INC

Explore why Aurinia Pharmaceuticals saw a 2.54% jump, trading above its 200‑day average amid growing investor interest in immunosuppressive biotech.

Discover why Aurinia’s stock edges higher amid volatile market dynamics, weighing pipeline progress, revenue sustainability, and capital efficiency for investors.

Discover Aurinia (AUPH)’s steady rise above its 200‑day moving average, a promising sign for investors in immunosuppressive biopharma amid competitive market dynamics.